DRW Securities’s Caribou Biosciences CRBU Stock Holding History

DRW Securities’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22,200	Closed	-$28K	–	1340
2025 Q2	$28K	Buy	+22,200	New	+$21.8K	﹤0.01%	1053

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DRW Securities's CRBU Position: Q3 2025 in Review

DRW Securities sold out of Caribou Biosciences (CRBU) in Q3 2025, closing a stake of 22,200 shares — an estimated $28K sold.

DRW Securities first reported a position in CRBU in Q2 2025 and held it in 1 quarter. The position peaked at $28K in Q2 2025. 117 funds tracked by Wall St. Rank hold CRBU as of Q3 2025.

DRW Securities reported no remaining Caribou Biosciences position as of Q3 2025 after selling out during the quarter.
DRW Securities sold 22,200 Caribou Biosciences shares in Q3 2025, an estimated $28K.
DRW Securities first reported a position in Caribou Biosciences in Q2 2025 and held it in 1 quarter.
DRW Securities's Caribou Biosciences position peaked at $28K in Q2 2025.
117 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.